Cargando…
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
BACKGROUND: Contemporary screening for prostate cancer frequently identifies small volume, low-grade lesions. Some clinicians have advocated focal prostatic ablation as an alternative to more aggressive interventions to manage these lesions. To identify which patients might benefit from focal ablati...
Autores principales: | Catto, J W F, Robinson, M C, Albertsen, P C, Goepel, J R, Abbod, M F, Linkens, D A, Davis, M, Rosario, D J, Warren, A Y, Varma, M, Griffiths, D F, Grigor, K M, Mayer, N J, Oxley, J D, Deshmukh, N S, Lane, J A, Metcalfe, C, Donovan, J L, Neal, D E, Hamdy, F C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185935/ https://www.ncbi.nlm.nih.gov/pubmed/21863028 http://dx.doi.org/10.1038/bjc.2011.314 |
Ejemplares similares
-
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020) -
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011) -
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022) -
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
por: Sanghera, S., et al.
Publicado: (2020) -
Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)